Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov:80:32-6.
doi: 10.1016/j.ypmed.2015.04.017. Epub 2015 Apr 30.

Interim treatment: Bridging delays to opioid treatment access

Stacey C Sigmon  1
Affiliations

Interim treatment: Bridging delays to opioid treatment access

Stacey C Sigmon. Prev Med. 2015 Nov.

Abstract

Objective: Despite the undisputed effectiveness of agonist maintenance for opioid dependence, individuals can remain on waitlists for months, during which they are at significant risk for morbidity and mortality. To mitigate these risks, the Food and Drug Administration in 1993 approved interim treatment, involving daily medication+emergency counseling only, when only a waitlist is otherwise available. We review the published research in the 20years since the approval of interim opioid treatment.

Methods: A literature search was conducted to identify all randomized trials evaluating the efficacy of interim treatment for opioid-dependent patients awaiting comprehensive treatment.

Results: Interim opioid treatment has been evaluated in four controlled trials to date. In three, interim treatment was compared to waitlist or placebo control conditions and produced greater outcomes on measures of illicit opioid use, retention, criminality, and likelihood of entry into comprehensive treatment. In the fourth, interim treatment was compared to standard methadone maintenance and produced comparable outcomes in illicit opioid use, retention, and criminal activity.

Conclusions: Interim treatment significantly reduces patient and societal risks when conventional treatment is unavailable. Further research is needed to examine the generality of these findings, further enhance outcomes, and identify the patient characteristics which predict treatment response.

Keywords: Buprenorphine; Interim treatment; Methadone; Opioid dependence; Opioid treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adamson SJ, Sellman D. The pattern of intravenous drug use and associated criminal activity in patients on a methadone treatment waiting list. Drug Alcohol Rev. 1998;17:59–166. - PubMed
    1. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. Springer-Verlag; New York: 1991.
    1. Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, et al. Integrating buprenorphine treatment into office-based practice: A qualitative study. J. Gen. Intern. Med. 2009;24(2):218–225. - PMC - PubMed
    1. Becker WC, Fiellin DA. Provider satisfaction with office- based treatment of opioid dependence a systematic review. Subst. Abuse. 2006;26:15–22. - PubMed
    1. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: Psychiatric, medical and substance use correlates. Drug Alc. Depend. 2008;94:38–47. - PubMed

Publication types